CSL (CSJ) Price & Analysis

0 Followers

CSJ Stock Chart & Stats

CHF99.72

CHF0.00(0.00%)

At close: Jul 28 4:00 PM EDT

CHF99.72

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF63.75 - CHF113.65

Previous CloseN/A

Volume0.00

Average Volume (3M)18.00

Market Cap

CHF54.76B

Enterprise ValueCHF70.67B

Total Cash (Recent Filing)CHF1.51B

Total Debt (Recent Filing)CHF10.89B

Price to Earnings (P/E)―

Beta1.25

Next Earnings

Feb 09, 2027

EPS Estimate

3.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.29

Shares Outstanding479,884,280

10 Day Avg. Volume55

30 Day Avg. Volume18

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)3.74

Price to Sales (P/S)3.45

P/FCF Ratio18.88

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF106.59

Price Target Upside6.89% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)3.58

Revenue Forecast (FY)CHF9.14B

Bulls Say, Bears Say

Bulls Say

Cash GenerationStrong operating cash flow provides CSL with internal funding for research, manufacturing capacity, debt service and shareholder distributions. Positive free cash flow despite the reported loss demonstrates resilience in cash generation, although future conversion may remain uneven.

Transformation SavingsSavings delivered ahead of plan can strengthen margins and partly offset portfolio pressure over the next several periods. Reinvestment of part of the benefits into commercial and R&D activity also supports productivity while preserving resources for future growth.

Ig And Specialty Product GrowthImproving immunoglobulin momentum and successful specialty launches reinforce CSL Behring’s position in complex therapies. These products can support more durable growth through differentiated clinical offerings, broader market access and increasing commercial scale.

Bears Say

Large Impairments And LossThe scale of impairments and the statutory loss materially weaken reported earnings quality and reduce the equity cushion. They also indicate that parts of the portfolio have lost value, increasing pressure on management to restore returns through restructuring and execution.

Vifor Structural DeclineGeneric competition, the loss of Velphoro’s benefit and the EU TAVNEOS authorization revocation create persistent headwinds for Vifor. A projected 25% revenue decline can dilute group growth, reduce scale and require sustained portfolio remediation.

Albumin Pressure In ChinaChina’s cost-containment measures and lower market value are pressuring a significant CSL product area even as volumes stabilize. Continued albumin pricing pressure could constrain revenue quality and margins, making recovery dependent on market conditions and portfolio mix.

CSL News

CSL Seqirus expands U.S. availability of influenza vaccine

CSL (CMXHF) Seqirus announced expanded availability of influenza vaccine in the United States following the completion of its...

25d ago

CSL Names ViiV Healthcare Chief Deborah Waterhouse as New CEO

An update from CSL ( ($AU:CSL) ) is now available. CSL Limited has appointed Deborah Waterhouse as Chief...

4d ago

CSL to Roll Out New Haemonetics Plasma Platform Across U.S. Network

The latest announcement is out from CSL ( ($AU:CSL) ). CSL Limited has expanded its relationship with Haemonetics...

17d ago

CSL Raises US$1.5bn in Dual-Tranche Bond Deal to Refinance Debt

CSL ( ($AU:CSL) ) just unveiled an update. CSL Limited has raised US$1.5 billion through a dual-tranche corporate...

18d ago

CSL Strikes US$355m Deal to Co-Develop Rare Kidney and Liver Disease Drug

CSL ( ($AU:CSL) ) has provided an announcement. CSL Limited has entered an exclusive co-development and co-promotion agreement...

20d ago

CSL Updates Market on Ongoing On‑Market Share Buy‑Back

CSL ( ($AU:CSL) ) has issued an update. CSL Limited has continued its on‑market share buy‑back program, updating...

1M ago

CSL Continues Active On-Market Share Buy-Back Program

CSL ( ($AU:CSL) ) has provided an announcement. CSL Limited has issued an updated notification to the ASX...

1M ago

CSL Sets Date and Details for 2026 Annual General Meeting in Melbourne

The latest update is out from CSL ( ($AU:CSL) ). CSL has released the official Notice of Meeting...

1M ago

CSL Updates Market on Progress of Ongoing Share Buy‑Back

CSL ( ($AU:CSL) ) has shared an announcement. CSL Limited has provided a daily update on its on‑market...

1M ago

CSL upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital analyst Craig Wong-Pan upgraded CSL (CMXHF) to Outperform from Sector Perform with a A$213 price target...

1M ago

CSL Reports Ongoing Daily On-Market Share Buy-Back Activity

CSL ( ($AU:CSL) ) just unveiled an announcement. CSL Limited has issued an updated notification to the ASX...

1M ago

CSL Updates Dividend Notice With New Currency Conversion Details

CSL ( ($AU:CSL) ) has provided an update. CSL Limited, a leading biopharmaceutical group listed on the ASX...

1M ago

CSL downgraded to Neutral from Buy at Citi

Citi downgraded CSL (CMXHF) to Neutral from Buy with a price target of A$110, down from A$200. While...

6M ago

CSL downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded CSL (CMXHF) to Sector Perform from Outperform with a price target of A$176, down from...

9M ago

CSJ FAQ

What was CSL’s price range in the past 12 months?

CSL lowest stock price was CHF63.74 and its highest was CHF113.65 in the past 12 months.

What is CSL’s market cap?

CSL’s market cap is CHF54.76B.

When is CSL’s upcoming earnings report date?

CSL’s upcoming earnings report date is Feb 09, 2027 which is in 108 days.

How were CSL’s earnings last quarter?

CSL released its earnings results on Aug 17, 2026. The company reported CHF1.87 earnings per share for the quarter, missing the consensus estimate of CHF1.949 by -CHF0.079.

Is CSL overvalued?

According to Wall Street analysts CSL’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CSL pay dividends?

CSL does not currently pay dividends.

What is CSL’s EPS estimate?

CSL’s EPS estimate is 3.31.

How many shares outstanding does CSL have?

CSL has 479,884,280 shares outstanding.

What happened to CSL’s price movement after its last earnings report?

CSL reported an EPS of CHF1.87 in its last earnings report, missing expectations of CHF1.949. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of CSL?

Currently, no hedge funds are holding shares in CH:CSJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CSL Stock Smart Score

Outperform

Fundamentals

Return on Equity

-15.12%

Trailing 12-Months

Asset Growth

-14.61%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

CSL

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.

CSL (CSJ) Earnings & Revenues

Historic Earnings Reports

CSJ Company Deck

CSJ Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Negative

The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.View all CH:CSJ earnings summaries

CSJ Stock 12 Month Forecast

Average Price Target

CHF106.59

▲(6.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"65":"CHF65","80":"CHF80","95":"CHF95","110":"CHF110","125":"CHF125"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124.72408429999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF124.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.59347417674545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF106.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.016803,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF87.02</span>\n  </div></div>","useHTML":true}}],"tickPositions":[65,80,95,110,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.722,101.64523725384615,103.5684745076923,105.49171176153845,107.41494901538461,109.33818626923076,111.26142352307691,113.18466077692307,115.10789803076922,117.03113528461537,118.95437253846153,120.87760979230768,122.80084704615383,{"y":124.72408429999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.722,100.25057493667272,100.77914987334545,101.30772481001817,101.8362997466909,102.36487468336362,102.89344962003635,103.42202455670909,103.95059949338182,104.47917443005454,105.00774936672727,105.5363243034,106.06489924007272,{"y":106.59347417674545,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.722,98.74467715384615,97.7673543076923,96.79003146153846,95.81270861538461,94.83538576923077,93.85806292307691,92.88074007692308,91.90341723076922,90.92609438461538,89.94877153846153,88.97144869230769,87.99412584615385,{"y":87.016803,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.71,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.413,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.722,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >